BIO-TECHNE Corp Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price
BIO-TECHNE Corp (TECH) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price of $75.88 per share as of 2026-06-30, per its 10-K filed 2026-08-24.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice · last filed 2026-08-24
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price $75.88.
- 2025-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price $62.69.
- 2024-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price $53.57.
- 2023-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price $44.76.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price as first filed |
|---|---|---|
| 2026-06-30 | $75.88 10-K · filed 2026-08-24 | |
| 2025-06-30 | $62.69 10-K · filed 2026-08-24 | |
| 2024-06-30 | $53.57 10-K · filed 2026-08-24 | |
| 2023-06-30 | $44.76 10-K · filed 2025-08-22 | |
| 2022-06-30 | $36.99 10-K · filed 2024-08-22 | $147.97 10-K · filed 2022-08-24 |
| 2021-06-30 | $31.61 10-K · filed 2023-08-23 | $126.44 10-K · filed 2021-08-25 |
| 2020-06-30 | $112.60 10-K · filed 2022-08-24 | |
| 2019-06-30 | $98.70 10-K · filed 2021-08-25 | |
| 2018-06-30 | $90.75 10-K · filed 2020-08-26 | |
| 2017-06-30 | $82.93 10-K/A · filed 2019-11-06 | |
| 2016-06-30 | $75.74 10-K · filed 2018-08-27 | |
| 2015-06-30 | $72.72 10-K · filed 2017-09-07 | |
| 2014-06-30 | $69.49 10-K · filed 2016-08-29 | |
| 2013-06-30 | $65.04 10-K · filed 2015-08-31 | |
| 2012-09-30 | $62.84 10-Q · filed 2012-11-09 | |
| 2012-06-30 | $62.67 10-K · filed 2014-08-29 | |
| 2012-03-31 | $60.73 10-Q · filed 2012-05-10 | |
| 2011-12-31 | $60.43 10-Q · filed 2012-02-07 | |
| 2011-09-30 | $59.16 10-Q · filed 2011-11-09 | |
| 2011-06-30 | $58.80 10-K · filed 2013-08-29 | |
| 2010-06-30 | $51.96 10-K · filed 2012-08-29 | |
| 2009-06-30 | $48.96 10-K · filed 2011-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |